BC Week In Review | Aug 31, 2018
Company News

CNS company Seelos reverse merging with Apricus

Seelos Therapeutics Inc. (New York, N.Y.) will reverse-merge with Apricus Biosciences Inc. (NASDAQ:APRI). Seelos shareholders are expected to own about 86% of the merged company. Apricus shareholders are expected to own the remaining 14%, and...
BC Week In Review | Feb 23, 2018
Clinical News

Apricus get CRL for ED candidate Vitaros

Apricus Biosciences Inc. (NASDAQ:APRI) said it received a complete response letter to a resubmitted NDA for Vitaros alprostadil to treat erectile dysfunction. The company said FDA cited CMC and safety concerns specific to the 2.5%...
BioCentury | Jan 6, 2018

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Sep 29, 2017
Clinical News

FDA accepts resubmitted NDA for Apricus' Vitaros

FDA accepted for review a resubmitted NDA for Vitaros alprostadil from Apricus Biosciences Inc. (NASDAQ:APRI) to treat erectile dysfunction. The PDUFA date is Feb. 17, 2018. Vitaros is a topical prostaglandin E1 (PGE1) cream formulated...
BC Week In Review | Mar 17, 2017
Company News

Apricus, Ferring deal

Apricus sold to Ferring remaining ex-U.S. rights and assets related to erectile dysfunction drug Vitaros alprostadil for $11.5 million upfront, plus up to $700,000 for product inventory and up to $500,000 for transition assistance. Ferring...
BC Week In Review | Jan 20, 2017
Clinical News

Vitaros regulatory update

Apricus said Mexico approved Vitaros alprostadil to treat erectile dysfunction (ED). Ferring Pharmaceuticals A/S (Saint-Prex, Switzerland), which has exclusive rights to market Vitaros to treat ED in Latin America, plans to launch Vitaros next quarter...
BioCentury | Oct 3, 2016

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BioCentury | Jul 11, 2016

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Oct 12, 2015
Company News

Allergan, Apricus Biosciences deal

Allergan granted Apricus exclusive rights to develop and commercialize Vitaros alprostadil in the U.S. Allergan will receive $1 million up front and is eligible to receive a $1.5 million regulatory milestone payment, plus double-digit royalties....
Items per page:
1 - 10 of 316